Analysis of mRNA m6A modification and mRNA expression profiles in middle ear cholesteatoma

Introduction: Middle ear cholesteatoma is characterized by the hyperproliferation of keratinocytes. In recent decades, N6-methyladenosine (m6A) modification has been shown to play an essential role in the pathogenesis of many proliferative diseases. However, neither the m6A modification profile nor its potential role in the pathogenesis of middle ear cholesteatoma has currently been investigated. Therefore, this study aimed to explore m6A modification patterns in middle ear cholesteatoma. Materials and methods: An m6A mRNA epitranscriptomic microarray analysis was performed to analyze m6A modification patterns in middle ear cholesteatoma tissue (n = 5) and normal post-auricular skin samples (n = 5). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to predict the potential biological functions and signaling pathways underlying the pathogenesis of middle ear cholesteatoma. Subsequently, m6A modification levels were verified by methylated RNA immunoprecipitation–qPCR (MeRIP–qPCR) in middle ear cholesteatoma tissue and normal skin samples, respectively. Results: A total of 6,865 distinctive m6A-modified mRNAs were identified, including 4,620 hypermethylated and 2,245 hypomethylated mRNAs, as well as 9,162 differentially expressed mRNAs, including 4,891 upregulated and 4,271 downregulated mRNAs, in the middle ear cholesteatoma group relative to the normal skin group. An association analysis between methylation and gene expression demonstrated that expression of 1,926 hypermethylated mRNAs was upregulated, while expression of 2,187 hypomethylated mRNAs and 38 hypermethylated mRNAs was downregulated. Moreover, GO analysis suggested that differentially methylated mRNAs might influence cellular processes and biological behaviors, such as cell differentiation, biosynthetic processes, regulation of molecular functions, and keratinization. KEGG pathway analysis demonstrated that the hypermethylated transcripts were involved in 26 pathways, including the Hippo signaling pathway, the p53 signaling pathway, and the inflammatory mediator regulation of transient receptor potential (TRP) channels, while the hypomethylated transcripts were involved in 13 pathways, including bacterial invasion of epithelial cells, steroid biosynthesis, and the Hippo signaling pathway. Conclusion: Our study presents m6A modification patterns in middle ear cholesteatoma, which may exert regulatory roles in middle ear cholesteatoma. The present study provides directions for mRNA m6A modification-based research on the epigenetic etiology and pathogenesis of middle ear cholesteatoma.

[1]  Xia Li,et al.  The m6A methylation profiles of immune cells in type 1 diabetes mellitus , 2022, Frontiers in Immunology.

[2]  F. Tao,et al.  Insight into the physiological and pathological roles of USP44, a potential tumor target (Review) , 2022, Oncology letters.

[3]  H. Wan,et al.  The Regulation of the Hippo Pathway by Intercellular Junction Proteins , 2022, Life.

[4]  Fangfang Ge,et al.  METTL3/m6A/IFIT2 regulates proliferation, invasion and immunity in esophageal squamous cell carcinoma , 2022, Frontiers in Pharmacology.

[5]  Yan Du,et al.  APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway , 2022, Frontiers in Oncology.

[6]  C. G. Hansen,et al.  The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer , 2022, Clinical science.

[7]  Xiaolan Guo,et al.  The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma. , 2021, Biochemical and biophysical research communications.

[8]  Cheng Huang,et al.  N6 -Methyladenosine and Rheumatoid Arthritis: A Comprehensive Review , 2021, Frontiers in Immunology.

[9]  A. Homma,et al.  Notch Signaling in Acquired Middle Ear Cholesteatoma , 2021, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[10]  R. Minoda,et al.  Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma , 2020, PloS one.

[11]  Min Tang,et al.  The oncogenic role of MUC12 in RCC progression depends on c‐Jun/TGF‐β signalling , 2020, Journal of cellular and molecular medicine.

[12]  H. Kojima,et al.  L1CAM-ILK-YAP mechanotransduction drives proliferative activity of epithelial cells in middle ear cholesteatoma. , 2020, The American journal of pathology.

[13]  B. Yan,et al.  USP44 suppresses proliferation and enhances apoptosis in colorectal cancer cells by inactivating the Wnt/β‐catenin pathway via Axin1 deubiquitination , 2020, Cell biology international.

[14]  Noam Stern-Ginossar,et al.  The RNA modification N6-methyladenosine as a novel regulator of the immune system , 2020, Nature Immunology.

[15]  Tianyu Wang,et al.  Ubiquitin-specific protease-44 inhibits the proliferation and migration of cells via inhibition of JNK pathway in clear cell renal cell carcinoma , 2020, BMC Cancer.

[16]  B. Southern,et al.  TRPV4 Protects the Lung from Bacterial Pneumonia via MAPK Molecular Pathway Switching , 2020, The Journal of Immunology.

[17]  S. Jaffrey,et al.  Reading, writing and erasing mRNA methylation , 2019, Nature Reviews Molecular Cell Biology.

[18]  Michaela Frye,et al.  RNA modifications modulate gene expression during development , 2018, Science.

[19]  R. Flavell,et al.  RNA m6A modification and its function in diseases , 2018, Frontiers of Medicine.

[20]  J. Castle.  Cholesteatoma Pearls: Practical Points and Update , 2018, Head and Neck Pathology.

[21]  M. Wessels,et al.  Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection , 2018, Cell.

[22]  H. Kojima,et al.  Keratinocyte Growth Factor (KGF) Modulates Epidermal Progenitor Cell Kinetics through Activation of p63 in Middle Ear Cholesteatoma , 2018, Journal of the Association for Research in Otolaryngology.

[23]  H. Kojima,et al.  Evaluation of YAP signaling in a rat tympanic membrane under a continuous negative pressure load and in human middle ear cholesteatoma , 2017, Acta oto-laryngologica.

[24]  Tao Pan,et al.  Dynamic RNA Modifications in Gene Expression Regulation , 2017, Cell.

[25]  Samir Adhikari,et al.  Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. , 2016, Molecular cell.

[26]  Olivier Elemento,et al.  5′ UTR m6A Promotes Cap-Independent Translation , 2015, Cell.

[27]  Shu-Bing Qian,et al.  Dynamic m6A mRNA methylation directs translational control of heat shock response , 2015, Nature.

[28]  J. M. Izquierdo,et al.  T-cell intracellular antigens in health and disease , 2015, Cell cycle.

[29]  C. Kuo.  Etiopathogenesis of acquired cholesteatoma: Prominent theories and recent advances in biomolecular research , 2015, The Laryngoscope.

[30]  Jose Evandro Andrade Prudente de Aquino,et al.  Epidemiology of middle ear and mastoid cholesteatomas. Study of 1146 cases , 2011, Brazilian journal of otorhinolaryngology.

[31]  J. M. Izquierdo,et al.  Knockdown of T-cell intracellular antigens triggers cell proliferation, invasion and tumour growth. , 2011, The Biochemical journal.

[32]  Hiroshi Tanaka,et al.  MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer , 2010, International journal of cancer.

[33]  T. Yune,et al.  Expression of CYLD and NF-κB in Human Cholesteatoma Epithelium , 2010, Mediators of inflammation.

[34]  H. Sudhoff,et al.  Middle ear cholesteatoma , 2010, e-Neuroforum.

[35]  H. Shimoda,et al.  Confirmation of mucin in lymphatic vessels of acquired cholesteatoma , 2006, European Archives of Oto-Rhino-Laryngology and Head & Neck.

[36]  Tianyu Wang,et al.  Ubiquitin-speci c protease-44 inhibits the proliferation and migration of cells via inhibition of JNK pathway in clear cell renal cell carcinoma , 2021 .

[37]  T. Pan,et al.  Probing RNA Modification Status at Single-Nucleotide Resolution in Total RNA. , 2015, Methods in enzymology.

[38]  T. Suganuma,et al.  Histochemical demonstration of mucin in lymphatic vessels of human middle ear cholesteatoma , 2004, European Archives of Oto-Rhino-Laryngology.

[39]  T. Suganuma,et al.  Sialomucin in middle ear cholesteatoma perimatrix. , 1992, Acta oto-laryngologica.